bs-55208R [Primary Antibody]
STAT3 Polyclonal Antibody
www.biossusa.com
support@biossusa.com
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: STAT3

Specificity: KO-Validated

Clonality: Polyclonal

Isotype: IgG

Entrez Gene: 6774

Swiss Prot: P40763

Source: Recombinant fusion protein containing a sequence corresponding to amino acids 640-770 of human STAT3 (NP_644805.1).

Purification: Purified by Protein A.

Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles.

Background:

The protein encoded by this gene is a member of the STAT protein family. In response to cytokines and growth factors, STAT family members are phosphorylated by the receptor associated kinases, and then form homo- or heterodimers that translocate to the cell nucleus where they act as transcription activators. This protein is activated through phosphorylation in response to various cytokines and growth factors including IFNs, EGF, IL5, IL6, HGF, LIF and BMP2. This protein mediates the expression of a variety of genes in response to cell stimuli, and thus plays a key role in many cellular processes such as cell growth and apoptosis. The small GTPase Rac1 has been shown to bind and regulate the activity of this protein. PIAS3 protein is a specific inhibitor of this protein. Mutations in this gene are associated with infantile-onset multisystem autoimmune disease and hyper-immunoglobulin E syndrome. Alternative splicing results in multiple transcript variants encoding distinct isoforms.

Size: 100µL

Concentration: 1ug/ul

Applications: WB(1:1000-2000)

Predicted Molecular Weight: 83kDa/87kDa/88kDa


Cross Reactive Species: Human

For research use only. Not intended for diagnostic or therapeutic use.

PRODUCT SPECIFIC PUBLICATIONS
  • Haixiang Ding. et al. Ailanthone suppresses the activity of human colorectal cancer cells through the STAT3 signaling pathway. Int J Mol Med. 2022 Feb;49(2):1-11Read more>>
  • Leiming Sun. et al. Isoliquiritigenin attenuates acute renal injury through suppressing oxidative stress, fibrosis and JAK2/STAT3 pathway in streptozotocin-induced diabetic rats. Bioengineered. 2021;12(2):11188-112Read more>>
  • Yeke Wu. et al. Aconiti lateralis radix praeparata total alkaloids exert anti-RA effects by regulating NF-B and JAK/STAT signaling pathways and promoting apoptosis.. FRONT PHARMACOL. 2022 Sep;13:980229-980229Read more>>
  • Wang Yaxin. et al. Overexpression of estrogen receptor inhibits cellular functions of human hepatic stellate cells and promotes the anti-fibrosis effect of calycosin via inhibiting STAT3 phosphorylation. BMC PHARMACOL TOXICO. 2022 Dec;23(1):1-13Read more>>
  • Guo, Zhi-chen. et al. Porphyromonas gingivalis promotes the progression of oral squamous cell carcinoma by activating the neutrophil chemotaxis in the tumour microenvironment. CANCER IMMUNOL IMMUN. 2022 Dec;:1-17Read more>>
  • Yanan Hao. et al. Alginate Oligosaccharides Repair Liver Injury by Improving Anti-Inflammatory Capacity in a Busulfan-Induced Mouse Model. INT J MOL SCI. 2023 Jan;24(4):3097Read more>>
  • Wu Kunzhe. et al. Co-delivery of curcumin and si-STAT3 with a bioinspired tumor homing for polydopamine nanoparticles for synergistic osteosarcoma therapy. CANCER NANOTECHNOL. 2023 Dec;14(1):1-21Read more>>
  • Zhijie Wang. et al. Discovery of a Bromodomain and Extra Terminal Domain (BET) Inhibitor with the Selectivity for the Second Bromodomain (BD2) and the Capacity for the Treatment of Inflammatory Diseases. J MED CHEM. 2023;XXXX(XXX):XXX-XXXRead more>>
  • Hui Yan. et al. Elaboration a ROS-responsive darutigenol prodrug nanoassemblies for inflammatory arthritis treatment. NANO TODAY. 2024 Apr;55:10222Read more>>
  • Chenchen Sun. et al. STAT3 mediates ECM stiffness-dependent progression in ovarian cancer. MOL CELL BIOCHEM. 2024 Apr;:1-14Read more>>
  • Panhong Wu. et al. Rutin alleviates psoriasis-related inflammation in keratinocytes by regulating the JAK2/STAT3 signaling. SKIN RES TECHNOL. 2024 Aug;30(8):e70011Read more>>
VALIDATION IMAGES

Lane 1: Human Hela cell lysates; Lane 2: Human 293T cell lysates probed with STAT3 Polyclonal Antibody, Unconjugated (bs-55208R) at 1:1000 dilution and 4˚C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.


Lane 1: Hela cell lysates; Lane 2: STAT3 knockout (KO) HeLa cell lysates probed with STAT3 Polyclonal Antibody, Unconjugated (bs-55208R) at 1:1000 dilution and 4˚C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.


Lane 1: Mouse Heart tissue lysates; Lane 2: Mouse Kidney tissue lysates; Lane 3: Mouse Cerebrum tissue lysates; Lane 4: Rat Heart tissue lysates ; Lane 5: Rat Kidney tissue lysates ; Lane 6: Rat Cerebrum tissue lysates probed with STAT3 Polyclonal Antibody, Unconjugated (bs-55208R) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.


Lane 1: Human Hela cell (Control) lysates; Lane 2: STAT3 knockout (KO) Hela cell lysates probed with STAT3 Polyclonal Antibody, Unconjugated (bs-55208R) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.


25 ug total protein per lane of various lysates (see on figure) probed with STAT3 polyclonal antibody, unconjugated (bs-55208R) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.